TCTR20221026004Enrolling By Invitation3 期
Phase 3 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac COVID-19 vaccine boost in comparison to a viral vector-based COVID-19 vaccines
适应症
试验速览
- 阶段
- 3 期
- 状态
- Enrolling By Invitation
- 入组人数
- 4,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Willingness to provide a signed and dated informed consent form.
- •2. Stated willingness to comply with all study procedures and availability for entire duration of the study.
- •3. Be a Thai male or female 18 years of age or older who were previously vaccinated with two intramuscular doses of Pfizer-BioNTech or AstraZeneca or Sinovac vaccine with a minimum of 4 months from their second dose vaccination.
- •4. For females: Be of non-childbearing potential or willing to use appropriate contraceptive measures for 30 days prior to vaccination through two months after complete vaccination. Non-childbearing potential means being surgically sterilized or at least one year post-menopausal. Appropriate measures to prevent pregnancy include abstinence or adequate contraceptive precautions (intrauterine or implantable contraceptive device, oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam).
- •5. For healthy participants with pre-existing medical conditions: Be in stable condition that has not worsened over the three months before enrollment to require hospitalization or significant changes in therapy.
排除标准
- •1. Prior or planned administration of a non-study vaccine (licensed or investigational) within 30 days before and after vaccination.
- •2. History of allergic reactions or anaphylaxis to any previous immunizations.
- •3. History of allergies to eggs, chicken, or any components of the study vaccine.
- •4. Fever (greater than or equal to 38.0 Celsius) within the past 24 hours.
- •5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the study vaccine.
- •6. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban).
- •7. History of COVID-19 infection within the three months preceding the planned administration of the study vaccine.
- •8. History of bleeding disorder (exempli gratia: factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular (IM) injections or venipuncture.
- •9. History of cerebral venous sinus thrombosis, antiphospholipid syndrome or heparin induced thrombocytopenia and thrombosis (HITT or HIT type 2).
- •10. Any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data.
- •11. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed).
- •12. Being pregnant (i.e. a positive urine pregnancy test) or lactating during the immunization phase of the study.
- •13. Planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase through two months after vaccination.
- •14. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination (for corticosteroids, this means prednisone or equivalent, greater than or equal to 0.5 mg/kg/day; inhaled and topical steroids are allowed).
- •15 Compromised immune system diseases including cancer (except basal cell carcinoma), congenital or acquired immune deficiencies and uncontrolled autoimmune diseases, as per case history and/or physical examination.
- •16. Indications of drug abuse or excessive use of alcohol as deemed by the investigator to confound safety assessments or render the participant unable or unlikely to adhere to protocol requirements or provide accurate safety reports.
- •17. History of asplenia.
- •18. Unavailable for the entire trial period.
- •19. Any other findings the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
研究者
相似试验
尚未招募
3 期
Phase 3 study, to evaluate the safety and immunogenicity of HXP-GPOVac vaccine in comparison to AstraZeneca's AZD1222 COVID-19 vaccineHealthy male and female subjectsTCTR20220120002The Government Pharmaceutical Organization4,000
已完成
3 期
A phase 3 study to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus (RSV) prefusion F subunit vaccine in adultsNL-OMON52252Pfizer5,000
已完成
3 期
A clinical study to evaluate safety and compare immune responses of two formulations of a combined 5-in-1 DTwP-HepB-Hib vaccine in childreCTRI/2018/12/016692Shantha Biotechnics Pvt Ltd460
进行中（未招募）
不适用
A study to assess the immunogenicity and safety of PCV-13 during adjuvant chemotherapyNeoplasmsKCT0003379Chonnam National University Hospital Hwasun Hospital92
已完成
不适用
Phase III study to prove the efficacy, safety and tolerability of Silexan® in patients with anxiety disorderAnxiety disorder not otherwise specifiedMental and Behavioural DisordersOther anxiety disordersISRCTN13032035Dr. Willmar Schwabe GmbH & Co. KG (Germany)220